Cargando…

The Proliferation REduction with Vascular ENergy Trial (PREVENT)

PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Raizner, Albert E, Kaluza, Grzegorz L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59647/
https://www.ncbi.nlm.nih.gov/pubmed/11806768
http://dx.doi.org/10.1186/cvm-2-1-016
_version_ 1782120093414588416
author Raizner, Albert E
Kaluza, Grzegorz L
author_facet Raizner, Albert E
Kaluza, Grzegorz L
author_sort Raizner, Albert E
collection PubMed
description PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy.
format Text
id pubmed-59647
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-596472001-11-06 The Proliferation REduction with Vascular ENergy Trial (PREVENT) Raizner, Albert E Kaluza, Grzegorz L Curr Control Trials Cardiovasc Med Commentary PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy. BioMed Central 2001 2001-02-01 /pmc/articles/PMC59647/ /pubmed/11806768 http://dx.doi.org/10.1186/cvm-2-1-016 Text en Copyright © 2001 Raizner and Kaluza; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Commentary
Raizner, Albert E
Kaluza, Grzegorz L
The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title_full The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title_fullStr The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title_full_unstemmed The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title_short The Proliferation REduction with Vascular ENergy Trial (PREVENT)
title_sort proliferation reduction with vascular energy trial (prevent)
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59647/
https://www.ncbi.nlm.nih.gov/pubmed/11806768
http://dx.doi.org/10.1186/cvm-2-1-016
work_keys_str_mv AT raizneralberte theproliferationreductionwithvascularenergytrialprevent
AT kaluzagrzegorzl theproliferationreductionwithvascularenergytrialprevent
AT raizneralberte proliferationreductionwithvascularenergytrialprevent
AT kaluzagrzegorzl proliferationreductionwithvascularenergytrialprevent